Rhythm Pharmaceuticals Says Cash On-hand Expected To Support Planned Operations Into 2026
Portfolio Pulse from Benzinga Newsdesk
Rhythm Pharmaceuticals announced that its cash on-hand is expected to support planned operations into 2026. The company anticipates approximately $250 million to $270 million in Non-GAAP Operating Expenses for the year ending December 31, 2024.
August 06, 2024 | 11:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rhythm Pharmaceuticals expects its cash on-hand to support operations into 2026, with anticipated Non-GAAP Operating Expenses of $250M-$270M for 2024.
The announcement that Rhythm Pharmaceuticals has sufficient cash to support operations into 2026 is a positive indicator of financial stability. The anticipated Non-GAAP Operating Expenses for 2024 provide clarity on future financial planning, which is likely to be viewed favorably by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100